EC
ASMB icon

EntryPoint Capital’s Assembly Biosciences ASMB Stock Holding History

EntryPoint Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$344K Buy
+12,384
New +$353K 0.1% 410

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

EntryPoint Capital's ASMB Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Assembly Biosciences (ASMB) in Q1 2026: 12,384 shares worth $344K. The stake represents 0.1% of the portfolio and ranks #410 among its holdings.

75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • EntryPoint Capital held 12,384 shares of Assembly Biosciences worth $344K as of Q1 2026.
  • Assembly Biosciences was a new EntryPoint Capital position in Q1 2026.
  • Assembly Biosciences made up 0.1% of EntryPoint Capital's portfolio in Q1 2026, its #410 holding.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.